Ventos

Ventos Therapeutics is a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for autoimmune diseases and neurological disorders. Launched by Versant Ventures with a $70 million Series A, the company utilizes a structure-based drug discovery platform to target challenging proteins within the unfolded protein response (UPR) pathway. Its lead research efforts center on Inositol-requiring enzyme 1 alpha (IRE1α), a key sensor of cellular stress linked to neurodegeneration and inflammation. By designing highly selective inhibitors, Ventos aims to provide transformative treatments for conditions such as ALS and Alzheimer's disease. The company leverages high-resolution structural biology and computational chemistry to address targets previously considered undruggable. Ventos was incubated within Versant's Inception Discovery Engine and is headquartered in San Diego, California.